NCBI
PubMed
A service of the
U.S. National Library of Medicine
and the
National Institutes of Health
My NCBI
[Sign In]
[Register]
All Databases
PubMed
Nucleotide
Protein
Genome
Structure
OMIM
PMC
Journals
Books
Search
Database name
PubMed
Protein
Nucleotide
GSS
EST
Structure
Genome
Books
CancerChromosomes
Conserved Domains
dbGaP
3D Domains
Gene
Genome Project
GENSAT
GEO Profiles
GEO DataSets
HomoloGene
Journals
MeSH
NCBI Web Site
NLM Catalog
OMIA
OMIM
PMC
PopSet
Probe
Protein Clusters
PubChem BioAssay
PubChem Compound
PubChem Substance
SNP
SRA
Taxonomy
ToolKit
ToolKitAll
UniGene
UniSTS
for
Search term
Go
Clear
Advanced Search
Limits
Preview/Index
History
Clipboard
Details
Display
Summary
Brief
Abstract
AbstractPlus
Citation
MEDLINE
XML
UI List
LinkOut
ASN.1
Related Articles
Cited in Books
CancerChrom Links
Domain Links
3D Domain Links
dbGaP Links
GEO DataSet Links
Gene Links
Gene (OMIM) Links
Gene (GeneRIF) Links
Genome Links
Project Links
GENSAT Links
GEO Profile Links
HomoloGene Links
Nucleotide Links
Nucleotide (RefSeq) Links
Nucleotide (Weighted) Links
EST Links
EST (RefSeq) Links
GSS Links
GSS (RefSeq) Links
OMIA Links
OMIM (calculated) Links
OMIM (cited) Links
BioAssay Links
Compound Links
Compound (MeSH Keyword)
Compound (Publisher) Links
Substance Links
Substance (MeSH Keyword)
Substance (Publisher) Links
PMC Links
Cited in PMC
PopSet Links
Probe Links
Protein Links
Protein (RefSeq) Links
Protein (Weighted) Links
Protein Cluster Links
Cited Articles
SNP Links
SNP (Cited)
Structure Links
Taxonomy via GenBank
UniGene Links
UniSTS Links
Show
5
10
20
50
100
200
500
Sort By
Pub Date
First Author
Last Author
Journal
Title
Send to
Text
File
Printer
Clipboard
Collections
E-mail
Order
All: 1
Review: 0
Click to change filter selection through MyNCBI.
1:
Clin Infect Dis.
2008 Dec 1;47(11):1468-75.
Related Articles
,
Links
Comment in:
Clin Infect Dis. 2008 Dec 1;47(11):1476-8.
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.
Tedaldi E
,
Peters L
,
Neuhaus J
,
Puoti M
,
Rockstroh J
,
Klein MB
,
Dore GJ
,
Mocroft A
,
Soriano V
,
Clotet B
,
Lundgren JD
;
SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
.
Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
BACKGROUND: In the Strategic Management of Antiretroviral Therapy (SMART) study, the risk of opportunistic disease (OD) and/or death due to any cause was elevated in the drug conservation (i.e., interrupt antiretroviral therapy until the CD4(+) cell count is <250 cells/microL) group, compared with the viral suppression (continued use of antiretroviral therapy) group. We assessed whether participants with concurrent hepatitis had an increased risk of the end points evaluated in the SMART study. METHODS: Participants were classified as being positive for hepatitis B virus (HBV) if they had positive hepatitis B surface antigen results for >6 months and positive for HCV if they tested HCV antibody positive. The rate and hazard ratio (HR) of OD and/or death and its 2 components were compared by hepatitis status and drug conservation versus the viral suppression group. RESULTS: Among 5472 participants enrolled from 8 January 2002 through 11 January 2006, 930 (17%) were HBV positive and/or HCV positive. The relative risk of non-OD death in participants randomized to the drug conservation group versus the viral suppression group was comparable regardless of hepatitis status (HR for coinfected and HIV-monoinfected participants, respectively, 1.9 [95% confidence interval {CI}, 1.0-3.9 and 1.8 [95% CI, 0.9-3.4]). The rate of OD or death was 3.9 events per 100 person-years in the coinfected group and 2.0 per 100 person-years in the HIV-monoinfected group. This excess risk was due to a higher risk of non-OD death among the coinfected participants (HR, 3.6; 95% CI, 2.3-5.6), whereas the risk of OD was comparable (HR, 1.1; 95% CI, 0.7-1.8). The 3 leading causes of non-OD death in coinfected participants were unknown cause, substance abuse, and non-acquired immunodeficiency disease cancer. CONCLUSIONS: Interruption of antiretroviral therapy is particularly unsafe in persons with hepatitis virus coinfection. Although HCV- and/or HBV-coinfected participants constituted 17% of participants in the SMART study, almost one-half of all non-OD deaths occurred in this population. Viral hepatitis was an unlikely cause of this excess risk.
Publication Types:
Randomized Controlled Trial
Research Support, N.I.H., Extramural
PMID: 18959492 [PubMed - indexed for MEDLINE]
Display
Summary
Brief
Abstract
AbstractPlus
Citation
MEDLINE
XML
UI List
LinkOut
ASN.1
Related Articles
Cited in Books
CancerChrom Links
Domain Links
3D Domain Links
dbGaP Links
GEO DataSet Links
Gene Links
Gene (OMIM) Links
Gene (GeneRIF) Links
Genome Links
Project Links
GENSAT Links
GEO Profile Links
HomoloGene Links
Nucleotide Links
Nucleotide (RefSeq) Links
Nucleotide (Weighted) Links
EST Links
EST (RefSeq) Links
GSS Links
GSS (RefSeq) Links
OMIA Links
OMIM (calculated) Links
OMIM (cited) Links
BioAssay Links
Compound Links
Compound (MeSH Keyword)
Compound (Publisher) Links
Substance Links
Substance (MeSH Keyword)
Substance (Publisher) Links
PMC Links
Cited in PMC
PopSet Links
Probe Links
Protein Links
Protein (RefSeq) Links
Protein (Weighted) Links
Protein Cluster Links
Cited Articles
SNP Links
SNP (Cited)
Structure Links
Taxonomy via GenBank
UniGene Links
UniSTS Links
Show
5
10
20
50
100
200
500
Sort By
Pub Date
First Author
Last Author
Journal
Title
Send to
Text
File
Printer
Clipboard
Collections
E-mail
Order
About Entrez
Text Version
Entrez PubMed
Overview
Help
|
FAQ
Tutorials
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI
Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central
Write to the Help Desk
NCBI
|
NLM
|
NIH
Department of Health & Human Services
Privacy Statement
|
Freedom of Information Act
|
Disclaimer